Fecal microbiota transplantation for recurrent clostridium difficile infection and other conditions in children: A joint position paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

TY - JOUR

T1 - Fecal microbiota transplantation for recurrent clostridium difficile infection and other conditions in children

T2 - A joint position paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition

AU - Davidovics, Zev H.

AU - Michail, Sonia

AU - Nicholson, Maribeth R.

AU - Kociolek, Larry K.

AU - Pai, Nikhil

AU - Hansen, Richard

AU - Schwerd, Tobias

AU - Maspons, Aldo

AU - Shamir, Raanan

AU - Szajewska, Hania

AU - Thapar, Nikhil

AU - De Meij, Tim

AU - Mosca, Alexis

AU - Vandenplas, Yvan

AU - Kahn, Stacy A.

AU - Kellermayer, Richard

N1 - Funding Information: The authors gratefully acknowledge the guidance and support of Dr Andrew Grossman in developing, drafting, and revising this article. The authors also gratefully acknowledge the following: Cures Within Reach (PI: Kahn), The Neil and Anna Rasmussen Foundation (PI: Kahn), and the Hamel Family (PI: Kahn), CTSA KL2 award, No.UL1 TR000445 (PI Hartmann), Wagner Family led Gutsy Kids Fund (PI: Kellermayer), and the Klaasmeyer family funds for Primary Sclerosing Cholangitis research (PI: Kellermayer). Publisher Copyright: © 2019 EDP Sciences. All rights reserved.

PY - 2019/1

Y1 - 2019/1

N2 - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

AB - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.

KW - child

KW - Clostridium difficile

KW - fecal

KW - fecal transplantation

KW - microbiome

KW - microbiota

KW - pediatric

UR - https://www.scopus.com/pages/publications/85059225507

U2 - 10.1097/mpg.0000000000002205

DO - 10.1097/mpg.0000000000002205

M3 - Article

C2 - 30540704

SN - 0277-2116

VL - 68

SP - 130

EP - 143

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

IS - 1

ER -